Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.
Dirix, Luc; Swaisland, Helen; Verheul, Henk M. W.et al.
2016 • In Clinical Therapeutics, 38 (10), p. 2286-2299
[en] PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA-mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the potential of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) to alter the pharmacokinetic (PK) profile of olaparib following single oral tablet doses. METHODS: Two Phase I, open-label, non-randomized trials were conducted in patients with advanced solid tumors. In Study 7, patients received olaparib alone and co-administered with itraconazole; in Study 8, a separate group of patients received olaparib alone and co-administered with rifampin. No interaction between itraconazole and olaparib was concluded if two-sided 90% CIs for the treatment ratios of AUC and/or AUC0-t and Cmax fell within the bioequivalence range of 0.80-1.25. An interaction between rifampin and olaparib was concluded if the lower limit of the 90% CI for the treatment ratios was <0.5 (ie, >50% decrease in olaparib AUC or Cmax in the presence of rifampin compared with olaparib alone). FINDINGS: In Study 7 (N = 59; 17 male, 42 female), 56 and 53 patients were evaluable for PK analysis following treatment with olaparib alone and olaparib plus itraconazole, respectively; in Study 8 (N = 22; 4 male, 18 female), all patients were evaluable. Co-administration of olaparib with itraconazole resulted in a statistically significant increase in the relative bioavailability of olaparib: Cmax treatment ratio, 1.42 (90% CI, 1.33-1.52); mean AUC treatment ratio, 2.70 (90% CI, 2.44-2.97). Mean CL/F and Vz/F were reduced (8.16 vs 3.05 L/h and 192 vs 75.1 L), although mean t(1/2) was unchanged (15.0 vs 15.6 hours). Co-administration of olaparib with rifampin resulted in a statistically significant decrease in the relative bioavailability of olaparib: Cmax treatment ratio, 0.29 (90% CI, 0.24-0.33); mean AUC treatment ratio, 0.13 (90% CI, 0.11-0.16). CL/F and Vz/F were increased when olaparib and rifampin were co-administered (6.36 vs 48.3 L/h and 112 vs 1076 L); however, mean t(1/2) was unchanged (13.0 vs 15.8 hours). Safety data for olaparib following tablet dosing were consistent with the known safety profile. IMPLICATIONS: Exposure to olaparib was significantly increased when co-administered with the potent CYP3A4 inhibitor itraconazole, and significantly decreased when co-administered with the potent CYP3A4 inducer rifampin, compared with olaparib alone. Potent CYP3A4 enzyme inhibitors and inducers should be avoided during olaparib treatment. ClinicalTrials.gov identifiers: NCT01900028 (Study 7) and NCT01929603 (Study 8).
Disciplines :
Oncology
Author, co-author :
Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy ; Université de Liège > Département des sciences cliniques > Oncologie
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.
Publication date :
2016
Journal title :
Clinical Therapeutics
ISSN :
0149-2918
Publisher :
Excerpta Medica, United States - New Jersey
Volume :
38
Issue :
10
Pages :
2286-2299
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2016 Elsevier HS Journals, Inc. All rights reserved.
1 Murai, J., Huang, S.Y., Das, B.B., et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72 (2012), 5588–5599.
2 Evers, B., Drost, R., Schut, E., et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 14 (2008), 3916–3925.
3 Rottenberg, S., Jaspers, J.E., Kersbergen, A., et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105 (2008), 17079–17084.
4 Farmer, H., McCabe, N., Lord, C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nat 434 (2005), 917–921.
5 FDA. Olaparib. 2014. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm427598.htm. Accessed July 8, 2016.
6 European Medicines Agency. Lynparza (olaparib); EPAR. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/003726/human_med_001831.jsp. Accessed May 8, 2015.
7 Ledermann, J., Harter, P., Gourley, C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366 (2012), 1382–1392.
8 Ledermann, J., Harter, P., Gourley, C., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 15 (2014), 852–861.
9 Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation. J Clin Oncol 33 (2015), 244–250.
10 Mateo, J., Moreno, V., Gupta, A., et al. An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib. Target Oncol 11 (2016), 401–415.
11 AstraZeneca. Global Policy: Bioethics. 2015. https://www.astrazeneca.com/sustainability/responsible-research.html. Accessed: July 8, 2016.
12 Diczfalusy, U., Kanebratt, K.P., Bredberg, E., et al. 4Beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. Br J Clin Pharmacol 67 (2009), 38–43.
13 Diczfalusy, U., Nylen, H., Elander, P., et al. 4Beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71 (2011), 183–189.
14 Rolfo, C., Swaisland, H., Leunen, K., et al. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. Adv Ther 32 (2015), 510–522.
15 van de Merbel, N.C., Bronsema, K.J., van Hout, M.W., et al. A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4beta-hydroxycholesterol in human plasma. J Pharm Biomed Anal 55 (2011), 1089–1095.
16 Osanai, T., Ohkubo, T., Yasui, N., et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol 58 (2004), 476–481.
17 Burger, D.M., Agarwala, S., Child, M., et al. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob Agents Chemother 50 (2006), 3336–3342.
18 Waters, N.J., Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment. Br J Clin Pharmacol 79 (2015), 946–958.
19 Backman, J.T., Kivisto, K.T., Olkkola, K.T., et al. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54 (1998), 53–58.
20 Tapaninen, T., Backman, J.T., Kurkinen, K.J., et al. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 51 (2011), 359–367.
21 Boyd, M.A., Zhang, X., Dorr, A., et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 43 (2003), 1382–1391.
22 la Porte, C.J., Colbers, E.P., Bertz, R., et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 48 (2004), 1553–1560.
23 Peloquin, C.A., Namdar, R., Singleton, M.D., et al. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115 (1999), 12–18.
24 Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 84 (2008), 417–423.
25 Fong, P.C., Boss, D.S., Yap, T.A., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361 (2009), 123–134.
26 Audeh, M.W., Carmichael, J., Penson, R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376 (2010), 245–251.
27 Tutt, A., Robson, M., Garber, J.E., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376 (2010), 235–244.
28 Gelmon, K.A., Tischkowitz, M., Mackay, H., et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12 (2011), 852–861.
29 ClinicalTrials.gov. Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1). 2015. https://clinicaltrials.gov/ct2/show/NCT01844986?term=NCT01844986&rank=1. Accessed June 13, 2015.
30 ClinicalTrials.gov. Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy. 2013. https://clinicaltrials.gov/ct2/show/NCT01874353?term=NCT01874353&rank=1. Accessed June 15, 2015.
31 ClinicalTrials.gov. Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. 2013. https://clinicaltrials.gov/ct2/show/NCT01924533?term=olaparib&phase=2&rank=7. Accessed June 15, 2015.
32 ClinicalTrials.gov. Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments (SOLO3). 2014. https://clinicaltrials.gov/ct2/show/NCT02282020?term=olaparib&phase=2&rank=5. Accessed June 15, 2015.
33 ClinicalTrials.gov. Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy (POLO). 2014. https://clinicaltrials.gov/ct2/show/NCT02184195?term=olaparib&phase=2&rank=2. Accessed June 15, 2015.
34 ClinicalTrials.gov. Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA). 2014. https://clinicaltrials.gov/ct2/show/NCT02032823?term=olaparib&phase=2&rank=1. Accessed June 15, 2015.
35 ClinicalTrials.gov. Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD). 2013. https://clinicaltrials.gov/ct2/show/NCT02000622?term=olaparib&phase=2&rank=3. Accessed June 15, 2015.
